Report Overview

The Osteoporosis drugs market size in Kenya stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Osteoporosis is a Bone-Mineral Density (BMD) disease in which the bones become weak and brittle due to loss of bone density which increases the risk of fractures. The World Health Organization (WHO) operationally defines osteoporosis as a Bone Mineral Density (BMD) that falls 2.5 Standard Deviations (SD) below the mean for young healthy adults. Osteoporosis is common among females above age 50 due to menopause. A positive association between osteoporosis and advancing age, poverty, illiteracy, and being underweight was found. In Kenya, the prevalence of osteoporosis stands at 24.3% among women. It is often overlooked and undertreated because it is clinically silent unless it presents with a fracture. Osteoporosis is not regarded as a health priority in Kenya.

Market Drivers

The market is majorly driven due to the rising prevalence of Osteoporosis in urban population caused due to adoption of modern lifestyles, physical inactivity, dietary changes, and hormonal changes due to ageing. Rate of urbanization in Kenya is rapidly increasing with the current rate of 4.23%.

The increase in the prevalence of Osteoporosis is also attributed to increased alcohol consumption and smoking, low levels of Vitamin D and underlying medical conditions like chronic kidney disease (CKD). Osteoporosis is males is attributed to decline in the testosterone levels with ageing.

However, the side effects caused by the drugs is one of the restraining factors. Some of the drugs have been found to have carcinogenic effect.

Diagnosis is a challenge due to low index of suspicion and due to the limited number of DEXA machines in the country and Africa as a whole. Kenya has 2 DEXA machines that serve a population of 40 million and the greater East Africa region. This limits the growth of bone diseases therapeutics market. Low levels of awareness and lack of screening contribute to restraining factors for market growth.